Literature DB >> 8401371

1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry.

M M Bortin1, M M Horowitz, P A Rowlings, A A Rimm, K A Sobocinski, M J Zhang, R P Gale.   

Abstract

The International Bone Marrow Transplant Registry is an organization devoted to scientific research in BMT. More than 230 transplant teams worldwide contribute detailed information about recipients of allogeneic and syngeneic BMT for study. Results of analyses are published in medical journals and presented at national and international scientific meetings (more than 60 publications and more than 500 presentations in the past 4 years). This collaborative research program has grown rapidly with more than 2000 cases reported annually. This report summarizes results of several recent investigations and reviews the state of BMT in leukemia and aplastic anemia.

Entities:  

Mesh:

Year:  1993        PMID: 8401371

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

Review 2.  Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.

Authors:  R L Capizzi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

4.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) counteracts the inhibiting effect of monocytes on natural killer (NK) cells.

Authors:  G van den Bosch; F Preijers; A Vreugdenhil; J Hendriks; F Maas; T De Witte
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

5.  Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia.

Authors:  Shosaku Nomura; Tomoki Ito; Atsushi Satake; Kazuyoshi Ishii
Journal:  J Blood Med       Date:  2018-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.